Literature DB >> 7559466

Identification of critical determinants of alpha 1-adrenergic receptor subtype selective agonist binding.

J Hwa1, R M Graham, D M Perez.   

Abstract

alpha 1-Adrenergic receptor (AR) subtypes mediate many effects of the sympathetic nervous system. The three cloned subtypes (alpha 1a-AR, alpha 1b-AR, alpha 1d-AR), although structurally similar, bind a series of ligands with different relative potencies. This is particularly true for the alpha 1a-AR, which recognizes a number of agonists and antagonists with 5-50-fold higher affinity than the alpha 1b- or alpha 1d- subtypes. Since ligands bind to receptor-residues that are located in the transmembrane spanning domains, we hypothesize that subtype differences in ligand recognition are due to differences in the binding properties of nonconserved transmembrane residues. Using site-directed mutagenesis, selected putative ligand-binding residues in the alpha 1b-AR were converted, either individually or in combination, to the corresponding residues in the alpha 1a-AR. Mutation of two such residues (of approximately 172 amino acids in the transmembrane domains) converted the agonist binding profile entirely to that of the alpha 1a-AR. Over 80% of this conversion was due to an Ala204-->Val substitution; the remainder was due to the additional substitution of Leu314-->Met. To confirm that Ala204 and Leu314 are indeed critical for agonist subtype-selectivity, the equivalent residues in the alpha 1a-AR (Val185 and Met293) were reversed of that of the alpha 1b-AR. Correspondingly, the agonist-binding profile of this double alpha 1a-AR mutant reverted to that of the alpha 1b-AR. From these data, in conjunction with macromolecular modeling of the ligand-binding pocket, a model has been developed, which indicates that the determinants of these two residues for agonist subtype-selectivity are due not only to interactions between their side chains and specific ligand moieties but also to a critical interaction between these two amino acids.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559466     DOI: 10.1074/jbc.270.39.23189

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Advances in the design and synthesis of prazosin derivatives over the last ten years.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Expert Opin Ther Targets       Date:  2011-12-13       Impact factor: 6.902

2.  Nuclear localization drives α1-adrenergic receptor oligomerization and signaling in cardiac myocytes.

Authors:  Casey D Wright; Steven C Wu; Erika F Dahl; Alan J Sazama; Timothy D O'Connell
Journal:  Cell Signal       Date:  2011-11-18       Impact factor: 4.315

Review 3.  Structure-function of alpha1-adrenergic receptors.

Authors:  Dianne M Perez
Journal:  Biochem Pharmacol       Date:  2006-09-16       Impact factor: 5.858

4.  Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function.

Authors:  Beilei Lei; Daniel P Morris; Michael P Smith; Laura P Svetkey; Mark F Newman; Jerome I Rotter; Thomas A Buchanan; Stephen M Beckstrom-Sternberg; Eric D Green; Debra A Schwinn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-03-10       Impact factor: 3.000

5.  Discovery of Melanocortin Ligands via a Double Simultaneous Substitution Strategy Based on the Ac-His-dPhe-Arg-Trp-NH2 Template.

Authors:  Aleksandar Todorovic; Cody J Lensing; Jerry Ryan Holder; Joseph W Scott; Nicholas B Sorensen; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-06-11       Impact factor: 4.418

6.  Probing the correlation between ligand efficacy and conformational diversity at the α1A-adrenoreceptor reveals allosteric coupling of its microswitches.

Authors:  Feng-Jie Wu; Lisa M Williams; Alaa Abdul-Ridha; Avanka Gunatilaka; Tasneem M Vaid; Martina Kocan; Alice R Whitehead; Michael D W Griffin; Ross A D Bathgate; Daniel J Scott; Paul R Gooley
Journal:  J Biol Chem       Date:  2020-04-17       Impact factor: 5.157

7.  Adrenergic α₁ receptor activation is sufficient, but not necessary for phrenic long-term facilitation.

Authors:  A G Huxtable; P M MacFarlane; S Vinit; N L Nichols; E A Dale; G S Mitchell
Journal:  J Appl Physiol (1985)       Date:  2014-02-13

8.  New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues.

Authors:  J Stitham; E Arehart; S R Gleim; N Li; K Douville; J Hwa
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

Review 9.  Nuclear compartmentalization of α1-adrenergic receptor signaling in adult cardiac myocytes.

Authors:  Steven C Wu; Timothy D OʼConnell
Journal:  J Cardiovasc Pharmacol       Date:  2015-02       Impact factor: 3.105

10.  Orthosteric binding of ρ-Da1a, a natural peptide of snake venom interacting selectively with the α1A-adrenoceptor.

Authors:  Arhamatoulaye Maïga; Jon Merlin; Elodie Marcon; Céline Rouget; Maud Larregola; Bernard Gilquin; Carole Fruchart-Gaillard; Evelyne Lajeunesse; Charles Marchetti; Alain Lorphelin; Laurent Bellanger; Roger J Summers; Dana S Hutchinson; Bronwyn A Evans; Denis Servent; Nicolas Gilles
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.